Logo image of SXTP

60 DEGREES PHARMA INC (SXTP) Stock Fundamental Analysis

NASDAQ:SXTP - Nasdaq - US83006G2030 - Common Stock - Currency: USD

0.4433  -0.03 (-6.16%)

Fundamental Rating

2

Taking everything into account, SXTP scores 2 out of 10 in our fundamental rating. SXTP was compared to 194 industry peers in the Pharmaceuticals industry. While SXTP seems to be doing ok healthwise, there are quite some concerns on its profitability. SXTP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SXTP has reported negative net income.
In the past year SXTP has reported a negative cash flow from operations.
SXTP Yearly Net Income VS EBIT VS OCF VS FCFSXTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -2M -4M -6M

1.2 Ratios

The Return On Assets of SXTP (-113.00%) is worse than 79.46% of its industry peers.
Looking at the Return On Equity, with a value of -138.85%, SXTP is doing worse than 64.32% of the companies in the same industry.
Industry RankSector Rank
ROA -113%
ROE -138.85%
ROIC N/A
ROA(3y)-277.62%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SXTP Yearly ROA, ROE, ROICSXTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 0 -100 -200 -300 -400

1.3 Margins

SXTP has a Gross Margin of 10.73%. This is comparable to the rest of the industry: SXTP outperforms 48.65% of its industry peers.
The Profit Margin and Operating Margin are not available for SXTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SXTP Yearly Profit, Operating, Gross MarginsSXTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 0 -500 -1K -1.5K -2K

More info and screens

4

2. Health

2.1 Basic Checks

SXTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SXTP has more shares outstanding
SXTP has a better debt/assets ratio than last year.
SXTP Yearly Shares OutstandingSXTP Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 1M 2M 3M 4M 5M
SXTP Yearly Total Debt VS Total AssetsSXTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

Based on the Altman-Z score of -9.02, we must say that SXTP is in the distress zone and has some risk of bankruptcy.
SXTP has a worse Altman-Z score (-9.02) than 71.89% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that SXTP is not too dependend on debt financing.
The Debt to Equity ratio of SXTP (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -9.02
ROIC/WACCN/A
WACC4.72%
SXTP Yearly LT Debt VS Equity VS FCFSXTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 10M -10M -20M

2.3 Liquidity

SXTP has a Current Ratio of 5.26. This indicates that SXTP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.26, SXTP is in the better half of the industry, outperforming 66.49% of the companies in the same industry.
A Quick Ratio of 4.91 indicates that SXTP has no problem at all paying its short term obligations.
SXTP has a Quick ratio of 4.91. This is in the better half of the industry: SXTP outperforms 65.95% of its industry peers.
Industry RankSector Rank
Current Ratio 5.26
Quick Ratio 4.91
SXTP Yearly Current Assets VS Current LiabilitesSXTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SXTP have decreased strongly by -230.74% in the last year.
SXTP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -35.93%.
SXTP shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -51.20% yearly.
EPS 1Y (TTM)-230.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.06%
Revenue 1Y (TTM)-35.93%
Revenue growth 3Y-51.2%
Revenue growth 5YN/A
Sales Q2Q%164.71%

3.2 Future

SXTP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.42% yearly.
Based on estimates for the next years, SXTP will show a very strong growth in Revenue. The Revenue will grow by 151.54% on average per year.
EPS Next Y54.66%
EPS Next 2Y35.85%
EPS Next 3Y25.42%
EPS Next 5YN/A
Revenue Next Year151.05%
Revenue Next 2Y162.83%
Revenue Next 3Y151.54%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SXTP Yearly Revenue VS EstimatesSXTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2M 4M 6M
SXTP Yearly EPS VS EstimatesSXTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SXTP. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SXTP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SXTP Price Earnings VS Forward Price EarningsSXTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SXTP Per share dataSXTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

SXTP's earnings are expected to grow with 25.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.85%
EPS Next 3Y25.42%

More info and screens

0

5. Dividend

5.1 Amount

SXTP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

60 DEGREES PHARMA INC

NASDAQ:SXTP (2/21/2025, 1:27:08 PM)

0.4433

-0.03 (-6.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-14 2024-11-14/dmh
Earnings (Next)N/A N/A
Inst Owners3.02%
Inst Owner Change148.19%
Ins Owners10.41%
Ins Owner Change9.31%
Market Cap3.26M
Analysts80
Price Target3.47 (682.77%)
Short Float %6.37%
Short Ratio0.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-38.85%
Min EPS beat(2)-48.37%
Max EPS beat(2)-29.33%
EPS beat(4)1
Avg EPS beat(4)-7.57%
Min EPS beat(4)-72.17%
Max EPS beat(4)119.61%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-43.68%
Min Revenue beat(2)-45.31%
Max Revenue beat(2)-42.06%
Revenue beat(4)0
Avg Revenue beat(4)-35.64%
Min Revenue beat(4)-45.31%
Max Revenue beat(4)-11.04%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-38.18%
EPS NQ rev (1m)9.09%
EPS NQ rev (3m)-566.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.67%
Revenue NQ rev (1m)-16.67%
Revenue NQ rev (3m)-28.57%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-34.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.05
P/FCF N/A
P/OCF N/A
P/B 0.54
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-9.12
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.55
OCFYN/A
SpS0.06
BVpS0.82
TBVpS0.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -113%
ROE -138.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.73%
FCFM N/A
ROA(3y)-277.62%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 549.4%
Cap/Sales 53.09%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.26
Quick Ratio 4.91
Altman-Z -9.02
F-Score3
WACC4.72%
ROIC/WACCN/A
Cap/Depr(3y)176.18%
Cap/Depr(5y)N/A
Cap/Sales(3y)19.34%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-230.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-110.06%
EPS Next Y54.66%
EPS Next 2Y35.85%
EPS Next 3Y25.42%
EPS Next 5YN/A
Revenue 1Y (TTM)-35.93%
Revenue growth 3Y-51.2%
Revenue growth 5YN/A
Sales Q2Q%164.71%
Revenue Next Year151.05%
Revenue Next 2Y162.83%
Revenue Next 3Y151.54%
Revenue Next 5YN/A
EBIT growth 1Y-90.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-335.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-349.8%
OCF growth 3YN/A
OCF growth 5YN/A